The UK and US have announced a significant bilateral deal that will preserve no levies on British medicine shipments going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to boost spending on pharmaceuticals through the NHS. This pledge secures that duties on these vital goods will stay at nothing for a duration of three years.
This deal comes after previous threats to significantly raise import taxes on branded pharmaceutical products, with potential rates floated reaching 100%.
"This arrangement with the United Kingdom reinforces the global environment for innovative medicines and brings much-needed equity to transatlantic drug exports," a release noted.
Commercial Impact
Drugs are one of the Britain's biggest export categories to the US, which is clearly the largest destination for large companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to last September, the UK sold pharmaceutical products worth billions to the US. This value accounted for nearly one-fifth of all goods exports in that period.
"This guarantee safeguards jobs, increases capital expenditure and paves the way for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The pact includes several specific changes from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it judges new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to control costs will be capped at 15%. Previously, refunds exceeded twenty percent.
Broader Context
The pact follows a long-running dispute between the drug companies and the UK government over spending levels and NHS adoption.
These tensions were intensified by arguments that US customers were paying a premium for the identical medicines than patients in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or abandoned, while substantial expansions have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the past decade.
